Wells Fargo’s Acurx Pharmaceuticals ACXP Stock Holding History

Wells Fargo’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.53K	Hold	2,300	–	–	﹤0.01%	5998
2025 Q4	$5.73K	Buy	+2,300	New	+$11K	﹤0.01%	6064
2024 Q2	–	Sell	-4	Closed	-$213	–	6867
2024 Q1	$213	Hold	4	–	–	﹤0.01%	6485
2023 Q4	$310	Hold	4	–	–	﹤0.01%	6495
2023 Q3	$116	Buy	4 +1	+33%	+$38	﹤0.01%	6730
2023 Q2	$172	Hold	3	–	–	﹤0.01%	6742
2023 Q1	$215	Hold	3	–	–	﹤0.01%	6757
2022 Q4	$243	Hold	3	–	–	﹤0.01%	6566
2022 Q3	$0	Buy	3 +2	+200%	+$150	﹤0.01%	6587
2022 Q2	$0	Hold	1	–	–	﹤0.01%	6736
2022 Q1	$0	Hold	1	–	–	﹤0.01%	6973
2021 Q4	$0	Hold	1	–	–	﹤0.01%	7165
2021 Q3	$0	Buy	+1	New	+$103	﹤0.01%	6913

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Wells Fargo's ACXP Position: Q1 2026 in Review

Wells Fargo held its Acurx Pharmaceuticals (ACXP) position steady in Q1 2026 at 2,300 shares worth $8.53K. The position accounts for ﹤0.01% of the portfolio, ranked #5998.

Wells Fargo first reported a position in ACXP in Q3 2021 and has held it in 13 quarters since. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Wells Fargo held 2,300 shares of Acurx Pharmaceuticals worth $8.53K as of Q1 2026.
Wells Fargo left its Acurx Pharmaceuticals share count unchanged in Q1 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5998 holding.
Wells Fargo first reported a position in Acurx Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.